Gastrodin Prevents Cognitive Decline Related to Cardiopulmonary Bypass
Status:
Unknown status
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The incidence of cognitive decline related to CPB ranges from 20% to 80%, which may affect
length of hospital stay, quality of life, the rehabilitation process, and work
performance.However, there is no method to prevent the decline.Gastrodin,the active
constituent of gastrodia elata, has been widely used for the treatment of paralysis,
hemiplegia, headache, vertigo, and Alzheimer's disease. Gastrodin is safe. No severe
side-effect has been observed in the treatment. We postulate that gastrodin would attenuate
the causative parameters of cognitive dysfunction related to CPB and would be an effective
drug to prevent the decline as a result.